Radiotheranostics in Prostate Cancer: Introduction and Overview

Nuclear medicine in the era of personalised medicine

“…Another area of increasing theranostic use is in the evaluation and treatment of patients with metastatic castrate‐resistant prostate carcinoma using radiolabelled prostate‐specific membrane antigen (PSMA) . PSMA is a transmembrane protein that is markedly overexpressed in prostate carcinoma . Numerous radiopharmaceuticals have emerged over the last few years to target PSMA for both diagnostic imaging and therapy .…”

PSMA PET: Transformational Change in Prostate Cancer Management?

“…Prostate-specific membrane antigen (PSMA) is not an antigen (it is a transmembrane protein), is not specific to the prostate gland (it is expressed in other normal tissues), and is not specific to prostate cancer (it is expressed in many benign conditions and cancers other than prostate cancer). Nevertheless, PSMA is highly relevant in prostate cancer theranostics in view of its marked overexpression in prostate cancer (1,2). Over the past several years, there have been major strides in the design, synthesis, and evaluation of smallmolecule radionuclides targeting PSMA for imaging and therapy (3).…”